Clinical Commissioning Policy Proposition:
Infliximab for the treatment of hidradenitis suppurativa
Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over, with Publications Gateway reference number assigned after it has been cleared by the Publications Gateway Team. Publications Gateway guidance and the IRB can be found on the Intranet.
Clinical Commissioning Policy Proposition:
Infliximab for the treatment of hidradenitis suppurativa

Version Number: NHS England A12X02/01

First published: March 2016

Prepared by NHS England Specialised Services Clinical Reference Group for Specialised Dermatology

Published by NHS England, in electronic format only.

Classification: OFFICIAL

The National Health Service Commissioning Board was established on 1 October 2012 as an executive non-departmental public body. Since 1 April 2013, the National Health Service Commissioning Board has used the name NHS England for operational purposes.
Equality Statement
NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.

Plain Language Summary
This policy proposition describes NHS England's commissioning approach for the use of infliximab in the treatment of people with hidradenitis suppurativa (HS).

Hidradenitis suppurativa (HS) is a painful, long-term skin disease that causes abscesses and scarring on the skin – usually around the groin, buttocks, breasts and armpits. The exact cause of HS is unclear, but the bumps and spots appear to be the result of blocked sweat glands and hair follicles. HS usually appears around the start of puberty, but it can appear at any age. When it does appear, HS is a lifelong, recurring condition that requires constant management.

The condition in its severest form, can have a very significant impact on quality of life with the need for hospital admissions and major impairment of physical and social functioning.

Infliximab is a medicine used for autoimmune diseases such as Crohn's disease. It dampens the body's immune response and has been shown to reduce inflammation (swelling). For this reason, there is clinical interest in whether it may be effectively used to treat patients with HS.

This policy proposition has considered the available evidence and found that there is currently insufficient evidence for NHS England to routinely commission infliximab for patients with hidradenitis suppurativa.
1. Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to not routinely commission infliximab for patients with hidradenitis suppurativa (HS).

For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition.

A final decision as to whether infliximab for hidradenitis suppurativa will be routinely commissioned is planned to be made by NHS England by June 2016 following a recommendation from the Clinical Priorities Advisory Group.

2. Proposed Intervention and Clinical Indication

Hidradenitis suppurativa (HS) is a chronic skin disease that causes abscesses and scarring on the skin- usually around the groin, buttocks, breasts and armpits. The disease tends to start in one area with the formation of a single, firm lesion. If the condition is not diagnosed or adequately controlled with medication, lesions are likely to become increasingly more common, spread to other areas of the body and grow in size. As the disease progresses, patients may also develop fistulas or sinus tracts, narrow channels that form under the skin and break out on the surface. Lesions, fistulas and sinus tracts are all prone to secondary infection which will usually require antibiotic treatment.

The condition in its severest form can have a very significant impact on quality of life, requiring hospital admissions and resulting in major impairment of physical and social functioning.

The exact cause of HS is unclear, however the lesions appear to be the result of blocked sweat glands and hair follicles. There are indications that genetic factors play a role in up to a third of patients, meaning the condition is more likely in those with relatives who are affected. The British Association of Dermatologists has also suggested that HS may be linked to Crohn's disease and have noted that many HS patients also suffer from another underlying autoimmune disorder.

Onset of HS is most common in late teens and early 20’s. HS outbreaks may persist for years with interspersed periods of inflammation. Early diagnosis is important as a successful combination of treatments can often help manage the condition and prevent the need for multiple surgeries. Due to the rarity and often embarrassing nature of the disease, many patients either don't seek diagnosis or are misdiagnosed.

Infliximab is a biologic therapy known to reduce the body's inflammatory response. There is substantive clinical evidence and experience of its effectiveness in other autoimmune disorders such as Crohn's disease and rheumatoid arthritis. For this reason, there is clinical interest in whether it may be an effective treatment option in patients with HS. Infliximab is not currently licenced for this indication and it is unlikely that an extension will be sought as the patent for infliximab has now expired and biosimilar products are now available.
3. Definitions

Hidradenitis suppurativa (HS) is a chronic skin disease characterised by clusters of abscesses or subcutaneous boil-like infections that most commonly affect sweat gland bearing areas such as the underarms, under the breasts, inner thighs, groin and buttocks.

Hurley’s staging system is used for the classification of patients with skin/dermatologic diseases. It separates patients into three groups based largely on the presence and extent of diseased tissue:

**Hurley Stage I:** Solitary or multiple isolated abscess formation without scarring or sinus tracts.

**Hurley Stage II:** Recurrent abscesses, single or multiple widely separated lesions with sinus tract formation. (Frequent restriction of movement which may require minor surgery such as incision or drainage.)

**Hurley Stage III:** Diffuse or broad involvement across a regional area with multiple interconnected sinus tracts and abscesses which impact on the ability of the patient to function.

Infliximab is an antibody administered intravenously that is licenced for treating a number of chronic inflammatory diseases. It works by blocking the effects of tumour necrosis factor alpha, a substance made by cells of the body which has an important role in promoting inflammation.

4. Aim and Objectives

This policy proposition aims to define NHS England’s commissioning position on infliximab as part of the treatment pathway for adult and adolescent patients with hidradenitis suppurativa.

The objective is to ensure evidence based commissioning with the aim of improving outcomes for adult and adolescent patients with hidradenitis suppurativa.

5. Epidemiology and Needs Assessment

While diagnosis of hidradenitis suppurativa is rare, the estimated prevalence is approximately 540,000 patients in England (NHS choices). Prevalence of HS is proportionally higher in women who are more frequently affected than men at a ratio of 2.7:1.

It is difficult to estimate how many patients would have moderate to severe HS. A study in North America found that 38.1% of newly diagnosed persons with hidradenitis suppurativa had moderate (Hurley Stage II) and 2.2% had severe (Hurley Stage III) symptoms. Based on these rates, it is possible that approximately 1,140 to 1,470 patients may have moderate to severe symptoms at time of diagnosis across England. Of those patients affected, an estimated 162 patients will have moderate to severe symptoms (defined as Hurley stage II-III) (British Medial Journal, Best Practice).

Due to a lack of research and licensed interventions for HS, the patient pathway is complex.
and it is difficult to estimate what proportion of patients fail to respond to standard treatment. Based on expert clinical opinion, it is estimated that this would be up to 100 HS patients per annum in England.

### 6. Evidence Base

<table>
<thead>
<tr>
<th>NHS England has concluded that there is currently not sufficient evidence to support a proposal for the routine commissioning of infliximab for patients with hidradenitis suppurativa. Opportunities for additional high quality research should be considered to provide further insight into the likely benefits and risks of using infliximab in the management of HS.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The evidence review looked to answer the following key questions:</td>
</tr>
<tr>
<td>Research question 1: Is infliximab clinically effective in limiting the frequency and severity of flares and avoiding sequential surgery to affected areas in patients who have moderate (Hurley stage II) or severe (Hurley stage III) hidradenitis suppurativa (HS), despite optimised treatment with multiple conventional therapies?</td>
</tr>
<tr>
<td>Research question 2: Is infliximab a safe and well tolerated drug to use in patients with hidradenitis suppurativa (Hurley stage II-III)?</td>
</tr>
<tr>
<td>Research question 3: Are there any particular subgroups of patients with hidradenitis suppurativa (indicated by severity, co-morbidities and demographic factors) who are likely to benefit more from the use of infliximab?</td>
</tr>
<tr>
<td>Research question 4: Is infliximab cost effective in the treatment of hidradenitis suppurativa (Hurley stage II-III)?</td>
</tr>
<tr>
<td><strong>In summary:</strong></td>
</tr>
<tr>
<td>- There are predominantly level 2/3 studies to support the clinical effectiveness of infliximab in patients with moderate to severe hidradenitis suppurativa (HS), with one small (N=38) RCT. The RCT found non-significant difference at the initial primary endpoint however significant benefit was found in post hoc analysis.</td>
</tr>
<tr>
<td>- Infliximab appears not to be associated with significant adverse effects in the majority of patients, noting that there is a lack of long term studies. Hypersensitivity reactions to infliximab are not uncommon.</td>
</tr>
<tr>
<td>- There is insufficient evidence to identify subgroups of patients with moderate to severe HS who may benefit more from infliximab.</td>
</tr>
<tr>
<td>- To date, no studies have been identified which evaluate the cost effectiveness of infliximab in the treatment of HS.</td>
</tr>
</tbody>
</table>
Research question 1: Is infliximab clinically effective in limiting the frequency and severity of flares and avoiding sequential surgery to affected areas in patients who have moderate (Hurley stage II) or severe (Hurley stage III) hidradenitis suppurativa, despite optimised treatment with multiple conventional therapies?

The evidence on clinical effectiveness of infliximab in the treatment of patients with HS is limited to a small, single-centre RCT and (predominantly) level 3 studies. This is not unexpected given the rarity of this condition.

The majority of patients who received infliximab were not in remission and had failed to respond to conventional treatments (systematic antibiotics, steroids and/or retinoid). Grant et al. (2010) in a double blinded, randomised control trial (level 1-) (n=38) found non-significant benefit in patients receiving infliximab at initial primary end point analysis when compared to placebo. Post-hoc analysis however showed a significant benefit, with reduction in the HS severity index score of 25-50% p<0.001. These findings are consistent with several systematic reviews (Brunasso et al., 2011 and Blok et al., 2013, level 2- and 3 respectively) that consist predominately of case series and case studies, and have shown a significant to moderate response in up to 90% of the patients. All of the systemic reviews evaluated have incorporated the only one RCT conducted to date (Grant et al., 2010), with duplication of evidence.

The baseline scores of both dermatology life quality index (DLQI) and visual analogue scale (VAS), that assess pain, in HS is high. Grant et al. (2010) observed a significant improvement in the DLQI (P=0.003), VAS (P<0.001) and physicians global assessment score (P<0.001) in the infliximab treatment group at 8 weeks. They also found a reduction in inflammatory markers, erythrocyte sedimentation rate and C-reactive protein in the infliximab group. These findings are consistent with other reported case series and case studies (level 3), with majority of follow-up to one year.

Van Rappard (2012), a small (N=20) retrospective cohort study, compared treatment outcomes of infliximab with another biological therapy and found that at one year, infliximab was more effective than adalimumab. There is insufficient evidence to compare other biological therapies with infliximab in treating severe to moderate HS.

The majority of studies have used 5mg/kg of intravenous infliximab, induction therapy (0, 2 and 6 weeks), and if continued then maintenance therapy at 8 weekly cycles. Moriarty et al., (2014) (level 3) described in three patients a weaning of response at 4 weeks during maintenance therapy, and were subsequently changed to 4 weekly cycles with an improvement in symptoms. It is widely recognised that infliximab can potentially lead to a loss of response long-term, attributed to immunogenicity and development of drug antibodies. Pradela et al. (2012) (level 3) assessed long-term efficacy of infliximab in HS in 10 patients and observed that relapse occurred in 50% of patients after a median period of 37 weeks with a median disease free period of 16 weeks.

Research question 2: Is infliximab a safe and well tolerated drug to use in patients with hidradenitis suppurativa (Hurley stage II-III)?

In the majority of patients, infliximab appears not to be associated with significant adverse effects. It has been associated with infusion reactions, and Grant et al. (2010) (level 1-)
Research question 3: Are there any particular subgroups of patients with hidradenitis suppurativa (indicated by severity, co-morbidities and demographic factors) who are likely to benefit more from the use of infliximab?

HS is associated with other inflammatory conditions, such as inflammatory bowel disease, SAPHO syndrome, psoriasis and pyoderma gangrenosum. A systematic review (level 3) evaluated the efficacy of infliximab in patients with HS and other inflammatory disease (Machet et al., 2013) and reported infliximab to be efficacious in 72% of the cohort (16/22 patients), with statistically insignificant higher failure rates when compared to patients with HS alone (27% vs 13%, P=0.1).

There is insufficient evidence to identify subgroups of patients with HS who may benefit more from infliximab. However, infliximab has been administered to patients with moderate to severe HS in all studies.

Research question 4: Is infliximab cost effective in the treatment of hidradenitis suppurativa (Hurley stage II-III)?

To date no studies have been identified which evaluate the cost effectiveness of infliximab in the treatment of HS.

7. Documents That Have Informed This Policy Proposition


8. Date of Review

This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned (expected by June 2016)